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a  b  s  t  r  a  c  t
HLA-C  is the  only  polymorphic  classical  HLA  I antigen  expressed  on  trophoblast  cells.  It is  known  that
higher  incidence  of C4d  deposition  on  trophoblast  cells  is present  in  women  with  recurrent  miscarriage.
C4d  is  a footprint  of antibody-mediated  classical  complement  activation.  Therefore,  this  study  hypothe-
size  that  antibodies  against  HLA-C  may  play  a role  in  the  occurrence  of  unexplained  consecutive  recurrent
miscarriage.
Present case  control  study  compared  the  incidence  of  HLA-C  speciﬁc  antibodies  in 95 women  with  at
least  three  consecutive  miscarriages  and  105 women  with  uneventful  pregnancy.  In the  ﬁrst  trimester
of  the  next  pregnancy,  presence  and speciﬁcity  of  HLA  antibodies  were  determined  and their  comple-
ment  ﬁxing  ability.  The  incidence  of  HLA  antibodies  was  compared  with  uni- and  multivariate  logistic
regression  models  adjusting  for possible  confounders.
Although  in  general  a higher  incidence  of  HLA  antibodies  was  found  in  women  with  recurrent  miscar-
riage  31.6%  vs.  in control  subjects  9.5%  (adjusted  OR 4.3,  95%  CI  2.0–9.5),  the  contribution  of antibodies
against  HLA-C  was signiﬁcantly  higher  in  women  with  recurrent  miscarriage  (9.5%)  compared  to  women
with  uneventful  pregnancy  (1%)  (adjusted  OR 11.0,  95%  CI 1.3–89.0).  In contrast  to  the  control  group,
HLA-C  antibodies  in the  recurrent  miscarriage  group  were  more  often  able  to bind  complement.
The  higher  incidence  of  antibodies  speciﬁc  for HLA-C  in women  with  recurrent  miscarriage  suggests
that  HLA-C  antibodies  may  be  involved  in the  aetiology  of  unexplained  consecutive  recurrent  miscarriage.
©  2016 Elsevier  Ireland  Ltd.  All  rights  reserved.. Introduction
About 1–3% of all couples are confronted with recurrent
iscarriage, which is internationally deﬁned as ≥3 consecutive
iscarriages before 20 weeks of gestation (Coulam, 1991). Recur-
ent miscarriage is a heterogeneous disorder. Possible etiologic
actors include uterine anomalies, endocrine disorders, acquired
hrombophilia (anti-phospholipid syndrome), hereditary throm-
ophilia, or balanced translocations in the maternal or paternal
Abbreviations: LMWH,  low molecular weight heparin; LUMC, Leiden University
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165-0378/© 2016 Elsevier Ireland Ltd. All rights reserved.DNA (Branch et al., 2010; Larsen et al., 2013). However, in many
couples no causal factor can be identiﬁed (Branch et al., 2010; Rai
and Regan, 2006).
During pregnancy the maternal immune system has to tolerate
the persistence of the semi-allogeneic fetal cells. The extravil-
lous trophoblasts, which is in direct contact with maternal cells,
expresses only HLA-C and the non-classical HLA-E, -F and -G.
Chimeric fetal cells in the peripheral circulation express all classical
HLA class I and II antigens. Approximately 30% of healthy women
develop HLA antibodies during pregnancy, the presence of these
antibodies increases after 28 weeks of pregnancy and antibodies
can still be present at time of a new conception (Regan et al., 1991;
van Kampen et al., 2001). Therefore, the incidence of HLA antibod-
ies in the ﬁrst trimester is higher in multiparous women than in
nulliparous women (van Kampen et al., 2001).
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Binding of antibodies to paternal HLA antigens of the fetus might
ead to complement ﬁxation and antibody mediated rejection of
he fetus. In women with recurrent miscarriage an increased depo-
ition of C4d, a marker of classical complement activation, was
ound at the maternal-fetal interface (Meuleman et al., 2015). In
pontaneous preterm birth C4d in fetal umbilical cord endothelium
as associated with circulating maternal anti-HLA class I antibod-
es (Lee et al., 2011). A recent meta-analysis showed no signiﬁcant
ssociation between HLA antibodies and the occurrence of recur-
ent miscarriage (Lashley et al., 2013), however the included studies
howed a high level of clinical and statistical heterogeneity. Inter-
stingly, the role of HLA-C speciﬁc antibodies has not been studied
et, while from transplantation settings we know that a propor-
ion of alloantibodies cause rejection, amongst others depending
n their ability to activate complement (Loupy et al., 2013).
We  hypothesize that antibody mediated reactivity plays a role
n unexplained recurrent miscarriage. Therefore, the incidence of
LA antibodies, especially those directed against the only polymor-
hic classical HLA I antigen expressed on trophoblast (HLA-C), is
ompared between women with recurrent miscarriage and women
ith uneventful pregnancy.
. Material and methods
.1. Subjects
We  performed a case control study. The case group was selected
rom the Habenox trial (NCT0095962) (Visser et al., 2011), a mul-
icentre multinational trial which investigated thrombophylaxis
enoxaparin (low molecular weight heparin (LMWH)), aspirin, or
ombination of both) for women with recurrent miscarriage with
nd without thrombophilia. The clinical work-up included docu-
entation of a standardised history from the couple, karyotyping
f the couple, an ultrasound or hysteroscopy, and thrombophilia
creening. Exclusion criteria for the Habenox trial were a history
f thromboembolism or bleeding disorders, allergy to aspirin or
noxaparin, uterine anomalies, cervical insufﬁciency, untreated
hyroid disease, poorly regulated diabetes mellitus, parental chro-
osomal abnormalities, and pregnancies achieved by assisted
eproductive techniques. Hereditary thrombophilia was deﬁned
y the presence of a factor V Leiden mutation, increased fac-
or II (prothrombin gene mutation), protein C or S deﬁciency,
ncreased factor VIII, or antithrombin deﬁciency. Acquired throm-
ophilia (anti-phospholipid syndrome) was deﬁned as the presence
f IgG anticardiolipin antibodies or lupus anticoagulant or IgG 2-
lycoprotein I antibodies in repeated samples taken 3 months apart
nd at least 6 weeks after pregnancy (Giannakopoulos et al., 2009).
To obtain a more homogenous case group in this case control
tudy, only women with three or more, consecutive miscarriages
rior to the 20th week of gestation without uterine anomalies and
arental chromosomal abnormalities were selected. Women  with
ereditary thrombophilia were not excluded, as the evidence that
ereditary thrombophilia is associated with recurrent miscarriage
s less clear (Larsen et al., 2013; McNamee et al., 2012).
The presence of HLA antibodies can be considered as a marker
or a broader immune response (Opelz, 2005). Although the pres-
nce of anti-phospholipid antibodies is highly associated with
ecurrent miscarriage (Chan et al., 2011; Larsen et al., 2013),
omen with acquired thrombophilia were not excluded since anti-
hospholipid antibodies are potential candidates for this broader
ntibody response. Sensitivity analyses were performed to eval-
ate the presence of HLA antibodies in women with and without
cquired thrombophilia in the case group compared to control sub-
ects.Fig. 1. Flow chart of the case group.
Both women with primary recurrent miscarriage (no history
of live birth) and secondary recurrent miscarriage (history of (a)
live birth(s)) were included. The Finnish women  were selected,
since blood samples were available from this group. Samples were
taken at the ﬁrst antenatal visit before enrolment in the Habenox
trial, and every 4 weeks, till the pregnancy ended. This pregnancy
was indicated as the index pregnancy. In the Habenox trial, 114
Finnish women were consecutive enrolled from January 2002 until
December 2007 and 95 cases were eligible for this case control
study (Fig. 1).
The control group consisted of women who had an uncompli-
cated index singleton pregnancy, ending in an uncomplicated live
birth without congenital abnormalities, delivering at the depart-
ment of Obstetrics at the Leiden University Medical Centre (LUMC)
in the Netherlands between June 2003 and June 2012. In total
105 women  were eligible and consisted of both nulliparous and
multiparous women. All these women had no recurrent miscar-
riage or complicated pregnancy (preeclampsia, Hemolysis Elevated
Liver enzymes and Low Platelets syndrome, preterm birth, preterm
rupture of membranes, fetal growth restriction, perinatal death or
maternal death deﬁned as described below) in history and current
pregnancy. Women  were at the time of inclusion healthy individu-
als with an uneventful medical history. Samples were taken in the
ﬁrst trimester during pregnancy, which was  indicated as the index
pregnancy.
2.2. Variables and deﬁnitions
From the cases and control subjects data was collected from
medical ﬁles. The following data was collected: personal charac-
teristics, intoxications, use of medication, general medical history,
information on previous blood transfusions and transplantations,
outcome and complications of all previous pregnancies before the
index pregnancy, gender of previous children, treatment for previ-
ous miscarriages, gestational age at blood sampling, outcome and
complications of index pregnancy, medication use during index
pregnancy, and neonatal characteristics.
Pregnancy induced hypertension was deﬁned as systolic
blood pressure above 140 mmHg  and/or diastolic pressure above
90 mmHg, combined with proteinuria as preeclampsia, preterm
birth as a delivery between 24 and 37 weeks gestation, fetal growth
restriction as birth weight below the 2.3th percentile for gesta-
tional age and sex (Kloosterman, 1970), perinatal death as fetal loss
after 22 weeks of gestation till 7 days after birth, and postpartum
haemorrhage as blood loss above 1000 mL  in the 24 h postpartum.
2.3. Antibody screeningThe presence of HLA antibodies was  determined in the ﬁrst
trimester (till 13 weeks gestation) of the index pregnancy, both
in cases and control subjects.
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cig. 2. Cross-analysis of single HLA-C antigen for triplet mismatches shown in a h
f  triplets are colored red and decreasing are colored blue. Mean triplet mismatch
etween group using average linking are given. (For interpretation of the reference
The detection of HLA class I and II antibodies in maternal sera
as performed by an enzyme-linked immunosorbent assay (LAT
M,  One Lambda, CA) with readouts at 630 nm, detecting both
omplement ﬁxing and non-complement ﬁxing antibodies. Posi-
ive sera (ratio patient/control >2.0) was further tested for HLA
ntibody speciﬁcity by the standard NIH complement dependent
ytotoxicity assay (Terasaki et al., 1978) against a panel of 54HLA-
yped individuals and for their class I and II speciﬁcity with Luminex
ingle antigen beads (Gen Probe, Stamford, CT) following the man-
facturer’s instructions. Puriﬁed anti-human C1q was  used in the
gG SAB assay to detect complement ﬁxing antibodies. An median
uorescence intensity >1000 was considered positive as reported
lsewhere (Billen et al., 2008; Zoet et al., 2011).
.4. Statistical analyses
For descriptive analysis of baseline characteristics between
ases and control subjects the Mann Whitney U test was  performed
nd for categorical variables the Chi-squared test, if expected
ounts were less than ﬁve Fisher’s exact test was used.
HLA antibody presence and speciﬁcity (HLA-A, HLA-B, HLA-C,
LA class I, and II antibodies) were compared between cases and
ontrol subjects.
Bias can arise due to genetic differences between the Finnish
ase group and the Dutch control group. As we had special
nterest in HLA antibodies against the most polymorphic antigen
n trophoblast the HLA-C antigen, we determined the rela-
ive immunogenicity of the different HLA-C antigens using the
LAMatchmaker program developed by Duquesnoy (2002) as pre-
iously described for HLA-A and -B (Dankers et al., 2004). The
umber of epitope (triplet) mismatches was calculated on basis
f polymorphic amino acid conﬁgurations that represent deﬁned
reas of HLA epitopes on protein sequences of HLA-A, -B, and -C
hains accessible to alloantibodies and depicted in a cross-analysis.p. The median number of triplet mismatches is colored white, increasing number
TMM) of speciﬁc HLA-C alleles towards all the other HLA-C alleles and clustering
lour in this ﬁgure legend, the reader is referred to the web version of this article.)
HLA-C*07 and C*17 showed the highest mean of triplet mismatches
within the HLA-C allele (Fig. 2), suggesting that these are the most
immunogenic antigens. The frequencies of the HLA-C alleles in
the Finnish and Dutch population were compared using www.
allelefrequencies.net and appeared to be comparable i.e. HLA-C*07
(0.30 vs. 0.33) and C*17 (0.022 vs. 0.004) between the Finnish and
Dutch population.
Furthermore, potential confounding factors for the presence of
HLA antibodies and the occurrence of recurrent miscarriage include
an older age, acquired thrombophilia, thyroid autoimmunity, pre-
vious pregnancy complications, and having a boy prior to the index
pregnancy.
More pregnancy complications are observed prior and subse-
quent to the miscarriages in women with recurrent miscarriage
(Nielsen et al., 2010a; Yang et al., 2006). In a recent meta-analysis
no beneﬁcial or harmful effect of HLA alloantibodies was observed
in pregnancy, however more studies are necessary to determine
deﬁnite effect of HLA antibodies on pregnancy outcome (Lashley
et al., 2013), and therefore pregnancy complications could still be
a potential confounder for the presence of HLA antibodies.
Furthermore, previous studies showed that recurrent miscar-
riage is more often preceded by a ﬁrstborn boy than girl (Nielsen
et al., 2008; Ooi et al., 2011). A boy prior to the index pregnancy
is related with presence of HLA antibodies (Nielsen et al., 2010b),
due to the higher incidence of pregnancy complications, if the child
preceding the secondary recurrent miscarriage is a boy compared
to a girl (Nielsen et al., 2010a).
Acquired thrombophilia was  not measured in the control group,
none of the cases and control subjects had thyroid disease, and
control subjects were selected on basis of uncomplicated previous
pregnancies. All these possible confounding factors, including hav-
ing a boy prior to the index pregnancy, could not be included in the
multivariate analysis. Therefore, the association between the pres-
ence of HLA antibodies and recurrent miscarriage was studied with
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Table  1
Baseline characteristics of subjects.
Recurrent miscarriage (N = 95) Uneventful pregnancy (N = 105)
Maternal age at time of index pregnancy (years; median [IQR]) 32 (29–35) 32 (27.5–35)
Body-mass index (kg/m2; median [IQR])b 22.6 (20.7–25.3) 23.2 (20.7–26.0)
Maternal smokingc 10 (11.2%) 9 (8.6%)
Blood  transfusions 0 0
Transplantation 0 0
Thrombophilia 24 n.t
V  Leiden mutation 8
Prothrombin gene mutation 2
Protein C or S deﬁciency 1
High factor VIII 0
Anti-thrombin deﬁciency 0
Anti-phospholipid syndrome 17
Gravidity at time of index pregnancy (median [IQR]) 5 (4–6)a 2 (1–3)
Parity  at time of index pregnancy (median [IQR]) 0 (0–1) 1 (0–1)
Nulliparous at time of index pregnancy 55 (57.9%) 51 (48.6%)
Previous miscarriages 95 (100%) 23 (21.9%)
(range) 3–8 0–2
Previous termination of pregnancy 6 (6.2%) 12 (11.5%)
(range) 0–2 0–2
Previous curettage 73 (76.8%)a 14 (13.3%)
Gestation blood sampling (days; median [IQR]) 67.5 (44.5–70)a 77 (71–84.5)
Having a boy prior to the index pregnancy 26 (65.0%) 34 (63%)























oa Compared with women with uneventful pregnancy p < 0.001.
b 11% missing values (4 of 95 cases and 18 of 105 controls).
c 4% missing values (6 of 95 cases and 2 of 105 controls).
ni- and multivariate logistic regression, adjusting for age as con-
inuous variable in a multivariate logistic regression analysis using
he enter method.
In the sensitivity analysis for parity the presence of HLA anti-
odies was compared between nulliparous, multiparous cases and
ontrol subjects.
Gravidity was not included in a sensitivity analysis because anti-
odies are rarely demonstrable before 28 weeks gestation (Regan
t al., 1991). Of the 50 pregnancies ending in a spontaneous mis-
arriage, only two women developed antibodies during the index
regnancy (Regan et al., 1991). As previous curettages and the ges-
ational age at the time of blood sampling can hypothetically affect
he incidence of HLA antibodies, these parameters were included
n sensitivity analyses.
Statistical analysis was performed using SPSS Statistics (version
0.0, IL, USA). Descriptive statistical analysis was performed using
raphPad Prism version 5.04 for Windows (GraphPad Software, CA,
SA, www.graphpad.com).
.5. Ethic statements
Approval to use blood samples for research from the Finnish
omen in the case group was given (NCT0095962). The deter-
ination of HLA antibodies in serum of women with uneventful
regnancies was approved by the Ethic Committee of the LUMC
P13.048).
. Results.1. Baseline characteristics of subjects
No differences between the cases and control subjects were
bserved with respect to maternal age, BMI, smoking habits, andparity (Table 1). In both groups the proportion of nulliparous
women was equal. None of the cases and control subjects had blood
transfusions or transplantation in their medical history. In the case
group the median consecutive miscarriage rate was  3, while 33
patients (34.7%) had 4 or more consecutive miscarriages. Of the 105
control subjects, 23 women  (21.9%) had at least one miscarriage
and 12 women (11.4%) had at least one termination of pregnancy
before the index pregnancy. Overall no differences were observed
in pregnancy complications between cases and control subjects
(Table 2).
3.2. The incidence of HLA antibodies is higher in women with
recurrent miscarriage
The incidence of HLA antibodies in the ﬁrst trimester was sig-
niﬁcantly higher in women  with recurrent miscarriage 31.6% vs. in
control subjects 9.5% (OR 4.3, 95% CI 2.0–9.5) (Fig. 3a). After adjust-
ment for age, in multivariate analysis, the estimator of interest did
not change (adjusted OR 4.3, 95% CI 2.0–9.5). The contribution of
HLA-C antibodies to the humoral sensitization was  signiﬁcantly
higher in women with recurrent miscarriage i.e. 9 out of 95 cases
compared to only one out of 105 control subjects (OR 10.8, 95% CI
1.3–87.6 and adjusted OR 11.0, 95% CI 1.3–89.0) (Fig. 3b). In 5 out of
9 women  with recurrent miscarriage these HLA-C antibodies were
C1q ﬁxing antibodies, the HLA-C antibodies found in the women
with an uneventful pregnancy were non-C1q ﬁxing antibodies.
As anti-phospholipid antibodies had not been measured in
the control subjects, we  could not correct in multivariate logis-
tic regression for the presence of anti-phospholipid antibodies, but
even after exclusion of the 17 cases with anti-phospholipid syn-
drome, the incidence of HLA antibodies was still higher in the
recurrent miscarriage group (OR 3.0, 95% CI 1.3–7.0).
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Table 2
Characteristics of the ongoing index pregnancy in subjects.
Recurrent miscarriage (N = 95) Uneventful pregnancy (N = 105)
Live births 60 (63.2%) 105 (100%)
Gestational age (days; median [IQR]) 281 (271–288) 281 (276–287)
Birthweight (gram; median [IQR]) 3372.5 (3137.7–3957.5) 3460 (3147.5–3802.5)
Blood  pressure (mmHg; median [IQR])c
Systolic 120 (115–130) 123 (120–130)
Diastolic 78 (73–90) 78 (71.2–80)
Pregnancy complications 19 (31.7%) 17 (16.2%)
Preterm birth 4 (6.8%)a 0 (0.0%)
Fetal  growth restriction 0 0
Fluxus 8 (14.3%)b 1 (1.0%)
Pregnancy induced hypertension 10 (16.7%) 16 (15.2%)
Preeclampsia 1 (1.7%) 0
HELLP  syndrome 0 0
Perinatal death 0 0
Maternal death 0 0
Data are n (%) unless otherwise indicated, IQR interquartile range, HELLP Hemolysis Elevated Liver enzymes and Low Platelets. All 2 tests or Mann-Whitney U test.
a Compared with women with uneventful pregnancy p < 0.05.
b Compared with women with uneventful pregnancy p < 0.001.
c 6.0% missing values (9 of 60 cases and 1 of 105 controls).
Fig. 3. Presence of HLA antibodies (a) and speciﬁc HLA antibodies (b) in cases and
control subjects. HLA antibodies in the ﬁrst trimester were signiﬁcantly higher in
women  with recurrent miscarriage 31.6% vs. in control subjects 9.5% (a). For speciﬁc














Fig. 4. Presence of HLA antibodies in cases and control subjects with and withoutLA I antigen expressed on trophoblast (HLA-C) were increased. In 9 out of 95 cases
LA-C antibodies were detected compared to only one out of 105 control subjects
b).
Sensitivity analysis for parity showed that HLA antibodies were
ore often present in nulliparous cases than in nulliparous con-
rol subjects (29.1% vs. 0%, p < 0.001). No signiﬁcant difference
as observed between mulitparous cases and control subjects in
LA antibodies (35% vs. 18.5%, p = 0.070). In nulliparous cases four
omen had HLA-C antibodies compared to none of the control sub-
ects (p = 0.050). Furthermore, multiparous cases had signiﬁcantly
ore often HLA-C antibodies than control subjects (12.5% vs. 1.9%, = 0.037).
Previous curettage was not associated with an increase of HLA
ntibodies, neither in cases nor in control subjects (Fig. 4). In
ddition, no HLA antibodies were detected in nulliparous controlprevious curettages. No association between the presence of HLA antibodies in the
cases or in the control subjects with and without previous curettage (p = 0.123 and
p  = 0.352 respectively).
subjects, although 7 control subjects had a termination of preg-
nancy before the index pregnancy and one control subject had two
terminations of pregnancy. In the case group the mean gestational
age at the time of blood sampling was  comparable in women with
and without HLA antibodies (61.4 vs. 58.0 days, p = 0.391). In the
control group gestational age at time of blood sampling was sig-
niﬁcantly later in women  with HLA antibodies (81.8 vs. 76.6 days,
p = 0.035).
4. Discussion
The incidence of HLA-antibodies in the ﬁrst trimester was found
to be signiﬁcantly increased in women  with recurrent miscarriage.
Particular relevant for the local situation in the placenta, is the
observation that signiﬁcantly more often HLA antibodies speciﬁc
for HLA-C are found in women  with recurrent miscarriage.
The strength of the study is that, in comparison to other studies
(Lashley et al., 2013), a large homogenous case group of women
with a history of recurrent miscarriage were selected. In addition
sensitivity analysis for parity was  performed. Finally, the detection
of the HLA-C speciﬁcity of the HLA antibodies is important, con-
sidering that HLA-C is the only classical HLA antigen expressed on
the trophoblast. Furthermore, by analysing the ability of the HLA-C
antibodies to ﬁx complement, a possible link can be made with the
previously observed increased C4d deposition on the trophoblast
in women with recurrent miscarriage (Meuleman et al., 2015).
HLA-antibodies in early pregnancy are associated with lower
chance of a live birth in women with recurrent miscarriage (Nielsen
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nce of HLA antibodies related to pregnancy outcome because the
se of medication. In our case group, all women used medication
s part of the randomized control trial, i.e. enoxaparin, aspirin, or
 combination of these two, during blood sampling for this study,
hich could inﬂuence pregnancy outcome. In vivo studies in mice
howed that treatment with heparin prevents complement acti-
ation and protects mice from pregnancy complications induced
y anti-phospholipid antibodies (Girardi et al., 2004). Recently,
 similar effect of LMWH  in women with at least two  consecu-
ive miscarriages or one late miscarriage has not been observed
Pasquier et al., 2015; Schleussner and Petroff, 2015), however the
ffect of LMWH  in a homogenous group of women with recurrent
iscarriage has not been studied yet.
Furthermore, the HLA typing of the fetus or products of con-
eption from the index pregnancy was unknown, which made it
mpossible to determine whether the HLA antibodies were spe-
iﬁc for the index pregnancy. Future research in a different group
f women with recurrent miscarriage, without using medication,
hould focus on the presence of HLA antibodies in ﬁrst trimester,
hether these antibodies are child speciﬁc, and relate this to preg-
ancy outcome.
The fact that the gestational age at blood sampling was signiﬁ-
antly higher in control subjects than in cases, could have affected
he results. However, a later gestational age is supposed to be asso-
iated with a higher production of HLA antibodies (Regan et al.,
991), whereas less HLA antibody production was seen in the con-
rols subjects, suggesting that the observed difference might even
e an underestimation.
The presence of HLA antibodies can be considered as a marker
or a broader immune response, as was previously shown in
LA identical family transplantations, where the presence of HLA
ntibodies was a risk factor for worse outcome, although HLA anti-
odies themselves could not have caused any harm (Opelz, 2005).
nti-phospholipid antibodies, which are highly associated with
ecurrent miscarriage (Larsen et al., 2013), are potential candi-
ates for this broader antibody response. No correction could be
ade in multivariate logistic regression for the presence of anti-
hospholipid antibodies since these antibodies were not measured
n the control subjects. However, even after exclusion of cases with
nti-phospholipid syndrome, a signiﬁcant association between the
resence of HLA antibodies and occurrence of recurrent miscarriage
as present.
Some studies suggest that the presence of speciﬁc antibodies
irected to the paternal HLA could be beneﬁcial for a pregnancy by
nhancing the development of maternal-fetal immunologic toler-
nce (Agrawal et al., 2002; Bartel et al., 2011; Coulam, 1992; Kishore
t al., 1996; Pandey et al., 2005), others demonstrate that HLA anti-
odies against the paternal antigens are rarely demonstrable before
8 weeks gestation in uneventful pregnancy (Regan et al., 1991),
hich is in line with our ﬁnding that none of the nulliparous con-
rol subjects had HLA antibodies. In contrast, almost one third of
he women with primary recurrent miscarriage produced HLA anti-
odies in the ﬁrst trimester. The presence of HLA-C antibodies in
omen with primary recurrent miscarriage may  partly explain the
igh incidence of C4d found in women with primary recurrent mis-
arriage shown previously (Meuleman et al., 2015). However, from
ransplantation settings it is known that not all alloantibodies cause
ejection and that their ability to activate complement might play
 determinative role (Loupy et al., 2013). The majority of the HLA-C
ntibodies in the case group were able to ﬁx complement, whereas
o complement ﬁxing HLA-C antibodies were found in the control
roup.In conclusion, in this study which included a homogenous well-
eﬁned group of women with recurrent miscarriage, a higher
ncidence of HLA antibodies was observed compared to women
ith an uneventful pregnancy. Especially, the presence of comple-ve Immunology 116 (2016) 28–34 33
ment ﬁxing HLA-C antibodies in relation to the selective expression
of HLA-C on trophoblast tissue might explain the aetiology in a
proportion of the women with recurrent miscarriage.
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